Daiyan Zhang, Liyang Lyu, Shuo Han, Jiaqi Xu, Guang Hu, Qi Zhao, Yuanjia Hu
Since the approval of the first chimeric antigen receptor (CAR)-T product in 2017, the number of new CAR-T clinical trials worldwide exceeds 100 per year. 1649 clinical studies have been conducted to explore possible future clinical applications of targets or target pairs through different biotechnologies. In this study, we aim to take a data-driven analytical approach to explore potential dual-target pairs based on clinical trial information. We screened 1283 non-withdrawal interventional CAR-T clinical trials spanning 96 different targets and 74 target pairs from clinicaltrials...
December 1, 2023: International Immunopharmacology
Jiali Lin, Wen Deng, Jing Liao, Diyang Ke, Ling Cui, Haibin Zhong, Kongqian Huang, Li Jiang, Qi Chen, Fan Xu, Fen Tang
Loss of retinal ganglion cells (RGCs) is a primary cause of visual impairment in glaucoma, the pathological process is closely related to neuroinflammation and apoptosis. B-cell activating factor (BAFF) is a fundamental survival factor mainly expressed in the B cell lineage. Evidence suggests its neuroprotective effect, but the expression and role in the retina have not yet been investigated. In this study, we adopt optic nerve crush (ONC) as an in vivo model and oxygen-glucose deprivation/reoxygenation (OGD/R) of RGCs as an in vitro model to investigate the expression and function of BAFF...
December 1, 2023: International Immunopharmacology
Xixi Zhao, Mengjie Liu, Chaofan Li, Xiaoxiao Liu, Jiaqi Zhao, Hongbing Ma, Shuqun Zhang, Jingkun Qu
Vitamin C (VitC) presents excellent anti-tumor effect for long time. Recently, high dose VitC achieved by intravenous administration manifests superior anti-tumor effect. However, the functions and detailed mechanisms of high dose VitC's role in cancer immunity are not fully understood. This study investigates the effect of high dose VitC on PD-L1 expression in triple negative breast cancer (TNBC) and the potential mechanism. Results showed VitC inhibited PD-L1 expression in breast cancer cell lines and enhanced anti-tumor effects of T cells...
December 1, 2023: International Immunopharmacology
Yun Sun, Defen Zhu, Lu Qu, Manping Li, Wenxia Du, Mingming Wang, Yi Zhang, Guifang Chen, Gaoxiong Rao, Xiaoling Yu, Xiangnong Wu, Feng Huang, Xiaoyun Tong
Atopic dermatitis (AD) is a chronic, inflammatory cutaneous disease driven by immune dysregulation. Catalpol is an iridoids, possessing anti-inflammatory, antioxidant, and neuroprotective activities. It can be added to food as a dietary supplement. To evaluate the effects and mechanisms of catalpol on AD, both in vitro and in vivo studies were conducted. It was found that catalpol downregulated the phosphorylation of Lyn and Syk to inhibit various downstream pathways, including intracellular Ca2+ elevation, cytokines generation, and histamine release, which ultimately controlled mast cell (MCs) degranulation...
December 1, 2023: International Immunopharmacology
Jie Yang, Jing Zheng, Yu Zhou, Quan Qiu, Jiabin Zhan, Xin Wei
PURPOSE: Sublingual immunotherapy (SLIT) has been proven to be an effective and safe treatment for patients with house dust mite (HDM)-induced allergic rhinitis (AR) to achieve short-term and long-term efficacy. This study aimed to investigate the relationship between SLIT duration and long-term efficacy. MATERIALS AND METHODS: This study involved 134 patients who underwent SLIT between 2019 and 2021 (in the 2-year group), between 2018 and 2021(in the 3-year group), or between 2017 and 2021 (in the 4-year group)...
November 24, 2023: American Journal of Otolaryngology
Yonatan Diamond, Maddie Gilsenan, Stacie Shiqi Wang, Diane Hanna, Rachel Conyers, Theresa Cole, David Hughes, Jacqueline Fleming, Deborah Meyran, Claudia Toro, Vajiranee Malalasekera, Seong Lin Khaw, Gabrielle M Haeusler
BACKGROUND: CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy is transforming care for pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). There are limited pediatric-specific data concerning the infection risks associated with CD19 CAR-T therapy and the adequacy of current antimicrobial prophylaxis guidelines for these patients. METHODS: We describe the antimicrobial prophylaxis used and the types of infectious occurring in the first 100 days following CAR-T therapy for relapsed or refractory B-cell ALL in children and adolescents (≤18 years) at our centre...
December 2, 2023: Transplant Infectious Disease: An Official Journal of the Transplantation Society
Xuemei Zhang, Youzhi Zhang, Qiaoyun Zhang, Mengyao Lu, Yuan Chen, Xiaoyu Zhang, Peng Zhang
The application of immune checkpoint inhibitor (ICI) using monoclonal antibodies has brought about a profound transformation in the clinical outcomes for patients grappling with advanced gastric cancer (GC). Nonetheless, despite these achievements, the quest for effective functional biomarkers for ICI therapy remains constrained. Recent research endeavours have shed light on the critical involvement of modified epigenetic regulators in the pathogenesis of gastric tumorigenesis, thus providing a glimpse into potential biomarkers...
December 2, 2023: Journal of Cellular and Molecular Medicine
Bin Yu, Junjie Luo, Yifei Yang, Ke Zhen, Binjie Shen
BACKGROUND: Patients with triple-negative breast cancer (TNBC) often have a poor prognostic outcome. Current treatment strategies cannot benefit all TNBC patients. Previous findings suggested pyroptosis as a novel target for suppressing cancer development, although the relationship between TNBC and pyroptosis-related genes (PRGs) was still unclear. METHODS: Gene expression data and clinical follow-up of TNBC patients were collected from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) and Gene Expression Omnibus (GEO)...
December 2, 2023: Journal of Gene Medicine
Jing Liang, Xiaohui Qiao, Luping Qiu, Huning Xu, Huijing Xiang, Hong Ding, Yu Chen
Due to the specific advantages of ultrasound (US) in therapeutic disease treatments, the unique therapeutic US technology has emerged. In addition to featuring a low-invasive targeted cancer-cell killing effect, the therapeutic US technology has been demonstrated to modulate the tumor immune landscape, amplify the therapeutic effect of other antitumor therapies, and induce immunosensitization of tumors to immunotherapy, shedding new light on the cancer treatment. Tremendous advances in nanotechnology are also expected to bring unprecedented benefits to enhancing the antitumor efficiency and immunological effects of therapeutic US, as well as therapeutic US-derived bimodal and multimodal synergistic therapies...
December 2, 2023: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
Chen Tang, Shaliu Fu, Xuan Jin, Wannian Li, Feiyang Xing, Bin Duan, Xiaojie Cheng, Xiaohan Chen, Shuguang Wang, Chenyu Zhu, Gaoyang Li, Guohui Chuai, Yayi He, Ping Wang, Qi Liu
BACKGROUND: The precise characterization of individual tumors and immune microenvironments using transcriptome sequencing has provided a great opportunity for successful personalized cancer treatment. However, the cancer treatment response is often characterized by in vitro assays or bulk transcriptomes that neglect the heterogeneity of malignant tumors in vivo and the immune microenvironment, motivating the need to use single-cell transcriptomes for personalized cancer treatment. METHODS: Here, we present comboSC, a computational proof-of-concept study to explore the feasibility of personalized cancer combination therapy optimization using single-cell transcriptomes...
December 1, 2023: Genome Medicine
Javiera Obreque, Luis Vergara-Gómez, Nicolás Venegas, Helga Weber, Gareth I Owen, Pablo Pérez-Moreno, Pamela Leal, Juan Carlos Roa, Carolina Bizama
In December 2022 the US Food and Drug Administration (FDA) removed the requirement that drugs in development must undergo animal testing before clinical evaluation, a declaration that now demands the establishment and verification of ex vivo preclinical models that closely represent tumor complexity and that can predict therapeutic response. Fortunately, the emergence of patient-derived organoid (PDOs) culture has enabled the ex vivo mimicking of the pathophysiology of human tumors with the reassembly of tissue-specific features...
December 2, 2023: Biological Research
Wei Wei, Fangfang Shi, Yang Xu, Yang Jiao, Ying Zhang, Qiuxiang Ou, Xue Wu, Lingyi Yang, Jinhuo Lai
BACKGROUND: ATM and ATR are two critical factors to regulate DNA damage response (DDR), and their mutations were frequently observed in different types of cancer, including non-small cell lung cancer (NSCLC). Given that the majority of identified ATM/ATR mutations were variants of uncertain significance, the clinical/molecular features of pathogenic ATM/ATR aberrations have not been comprehensively investigated in NSCLC. METHODS: Next-generation sequencing (NGS) analyses were conducted to investigate the molecular features in 191 NSCLC patients who harbored pathogenic/likely pathogenic ATM/ATR mutations and 308 NSCLC patients who did not have any types of ATM/ATR variants...
December 1, 2023: Journal of Translational Medicine
Xiangyu Wu, Tianhang Li, Rui Jiang, Xin Yang, Hongqian Guo, Rong Yang
The molecules of Major histocompatibility class I (MHC-I) load peptides and present them on the cell surface, which provided the immune system with the signal to detect and eliminate the infected or cancerous cells. In the context of cancer, owing to the crucial immune-regulatory roles played by MHC-I molecules, the abnormal modulation of MHC-I expression and function could be hijacked by tumor cells to escape the immune surveillance and attack, thereby promoting tumoral progression and impairing the efficacy of cancer immunotherapy...
December 2, 2023: Molecular Cancer
Rongyang Li, Jianhao Qiu, Zhan Zhang, Chenghao Qu, Zhanpeng Tang, Wenhao Yu, Yu Tian, Hui Tian
BACKGROUND: Lymphocyte-activation gene 3 (LAG3) is a recently discovered immune checkpoint molecule that has been linked to immunosuppression and the advancement of cancer in different types of solid tumors. This study aimed to evaluate the prognostic importance of LAG3 and its role in the immune system within solid tumors. METHODS: Extensive literature searches were conducted using the Pubmed, EMBASE, and Cochrane Library databases to identify relevant studies exploring the effect of LAG3 on survival outcomes...
December 2, 2023: Cancer Cell International
Anastasiia Kalinina, Elena Grigorieva, Anna Smirnova, Dmitry Kazansky, Ludmila Khromykh
BACKGROUND AND OBJECTIVE: Cyclophilin A (CypA) is an isomerase that functions as a chaperone, housekeeping protein, and cyclosporine A (CsA) ligand. Secreted CypA is a proinflammatory factor, chemoattractant, immune regulator, and factor of antitumor immunity. Experimental data suggest clinical applications of recombinant human CypA (rhCypA) as a biotherapeutic for cancer immunotherapy, stimulation of tissue regeneration, treatment of brain pathologies, and as a supportive treatment for CsA-based therapies...
December 1, 2023: European Journal of Drug Metabolism and Pharmacokinetics
Xiaoming Yang
The epidemic of corona virus disease 2019 (COVID-19) caused by severe acute respiratory syndrome Coronavirus 2 and its variants of concern (VOCs) has been ongoing for over 3 years. Antibody therapies encompassing convalescent plasma, hyperimmunoglobulin, and neutralizing monoclonal antibodies (mAbs) applied in passive immunotherapy have yielded positive outcomes and played a crucial role in the early COVID-19 treatment. In this review, the development path, action mechanism, clinical research results, challenges, and safety profile associated with the use of COVID-19 convalescent plasma, hyperimmunoglobulin, and mAbs were summarized...
December 2, 2023: Frontiers of Medicine
Suping Li, Zefang Lu, Suying Wu, Tianjiao Chu, Bozhao Li, Feilong Qi, Yuliang Zhao, Guangjun Nie
Systemic antiplatelet treatment represents a promising option to improve the therapeutic outcomes and therapeutic efficacy of chemotherapy and immunotherapy due to the critical contribution of platelets to tumour progression. However, until recently, targeting platelets as a cancer therapeutic has been hampered by the elevated risk of haemorrhagic and thrombocytopenic (low platelet count) complications owing to the lack of specificity for tumour-associated platelets. Recent work has advanced our understanding of the molecular mechanisms responsible for the contribution of platelets to tumour progression and metastasis...
December 1, 2023: Nature Reviews. Cancer
Xin Huang, Weiyue Zhang
Immune checkpoint blockade (ICB) therapy for tumors has arisen in growing interest. However, the low response rate of tumors to ICB is mainly attributed to the inhibitory infiltration of immune cells in the tumor microenvironment (TME). Despite the promising benefits of ICB, the therapeutic effects of antibodies are dependent on a high dose and long-term usage in the clinic, thereby leading to immune-related adverse effects. Accordingly, ICB combined with nano-delivery systems could be used to overcome T cell exhaustion, which reduces the side effects and the usage of antibodies with higher response rates in patients...
December 1, 2023: Small Methods
Sofia Edin, Björn Gylling, Xingru Li, Åsa Stenberg, Anna Löfgren-Burström, Carl Zingmark, Bethany van Guelpen, Ingrid Ljuslinder, Agnes Ling, Richard Palmqvist
BACKGROUND: The immune response has important clinical value in colorectal cancer (CRC) in both prognosis and response to immunotherapy. This study aims to explore tumour immune cell infiltration in relation to clinically well-established molecular markers of CRC. METHODS: Multiplex immunohistochemistry and multispectral imaging was used to evaluate tumour infiltration of cytotoxic T cells (CD8+ ), Th1 cells (T-bet+ ), T regulatory cells (FoxP3+ ), B cells (CD20+ ), and macrophages (CD68+ ) in a cohort of 257 CRC patients...
December 1, 2023: British Journal of Cancer
Nan Xu, Jianyong Zhuo, Yiyuan Chen, Renyi Su, Huan Chen, Zhensheng Zhang, Zhengxing Lian, Di Lu, Xuyong Wei, Shusen Zheng, Xiao Xu, Shuai Wang, Qiang Wei
BACKGROUND: N4-acetylcytidine (ac4C) is a conserved and abundant mRNA modification that controls protein expression by affecting translation efficiency and mRNA stability. Whether the ac4C modification of mRNA regulates hepatocellular carcinoma (HCC) development or affects the immunotherapy of HCC is unknown. METHODS: By constructing an orthotopic transplantation mouse HCC model and isolating tumour-infiltrated immunocytes, we evaluated the ac4C modification intensity using flow cytometry...
December 1, 2023: British Journal of Cancer
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.